Your browser doesn't support javascript.
loading
COVIDpro: Database for Mining Protein Dysregulation in Patients with COVID-19.
Zhang, Fangfei; Luna, Augustin; Tan, Tingting; Chen, Yingdan; Sander, Chris; Guo, Tiannan.
Afiliación
  • Zhang F; Fudan University, 220 Handan Road, Shanghai 200433, China.
  • Luna A; Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang Province 310024, China.
  • Tan T; Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang Province 310024, China.
  • Chen Y; Research Center for Industries of the Future, Westlake University, 600 Dunyu Road, Hangzhou, Zhejiang 310030, China.
  • Sander C; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, United States.
  • Guo T; Broad Institute of MIT and Harvard, Cambridge, Cambridge, Massachusetts 02142, United States.
J Proteome Res ; 22(9): 2847-2859, 2023 09 01.
Article en En | MEDLINE | ID: mdl-37555633
The ongoing pandemic of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 still has limited treatment options. Our understanding of the molecular dysregulations that occur in response to infection remains incomplete. We developed a web application COVIDpro (https://www.guomics.com/covidPro/) that includes proteomics data obtained from 41 original studies conducted in 32 hospitals worldwide, involving 3077 patients and covering 19 types of clinical specimens, predominantly plasma and serum. The data set encompasses 53 protein expression matrices, comprising a total of 5434 samples and 14,403 unique proteins. We identified a panel of proteins that exhibit significant dysregulation, enabling the classification of COVID-19 patients into severe and non-severe disease categories. The proteomic signatures achieved promising results in distinguishing severe cases, with a mean area under the curve of 0.87 and accuracy of 0.80 across five independent test sets. COVIDpro serves as a valuable resource for testing hypotheses and exploring potential targets for novel treatments in COVID-19 patients.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Proteome Res Asunto de la revista: BIOQUIMICA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Proteome Res Asunto de la revista: BIOQUIMICA Año: 2023 Tipo del documento: Article País de afiliación: China